← Eichor
Condition: Recurrent Renal Cell Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent Renal Cell Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized C
Phase N/A · 1 location(s) · Mingzhao Xiao · NCT06088134CAIX PET/ CT Guided Radiation Therapy in CcRCC.
NA · 1 location(s) · Peking University First Hospital · NCT07540260APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Phase 2 · 6 location(s) · Nationwide Children's Hospital · NCT05135975A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cel
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06447103Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During o
Phase 1/Phase 2 · 30 location(s) · Merck Sharp & Dohme LLC · NCT07049926SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Phase N/A · 2 location(s) · Peking University First Hospital · NCT06583070Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Phase N/A · 22 location(s) · UroGen Pharma Ltd. · NCT05874921Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC
Phase 2 · 7 location(s) · Advenchen Pharmaceuticals, LLC. · NCT05363280Kidney Cancer Observational Protocol
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06147349International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
Phase N/A · 37 location(s) · Azienda Ospedaliero-Universitaria Careggi · NCT05363657Combination of Toripalimab and JS004 Therapy for ccRCC
Phase 2 · 1 location(s) · Fudan University · NCT06690697Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6
Phase 3 · 124 location(s) · Merck Sharp & Dohme LLC · NCT07227402Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Phase 2 · 1 location(s) · Nagoya University · NCT06983210Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer
Phase N/A · 3 location(s) · Brigitta Rasmussen Villumsen · NCT07234656Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplast
Phase 1/Phase 2 · 28 location(s) · National Cancer Institute (NCI) · NCT04616560Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
Phase N/A · 1 location(s) · Tianjin Medical University Second Hospital · NCT07657325Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
Phase 2 · 2 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT057684649MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06823427Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Phase 2 · 1 location(s) · Peking University First Hospital · NCT06889649Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Phase 3 · 5 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT07197580Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.